Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. We sell different types of products and ...

The revised price target reflects a more conservative growth trajectory for Ingrezza, Neurocrine's lead product. Guggenheim also maintained a Buy rating but lowered the price target to $163 from $ ...

Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...